Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4609]

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukaemia and lymphoma

Machine learning helps in predicting when immunotherapy will be effective

Machine learning helps in predicting when immunotherapy will be effective

Targeted delivery of therapeutic RNAs only to cancer, no harm caused to healthy cells

Targeted delivery of therapeutic RNAs only to cancer, no harm caused to healthy cells

Cell-based immunotherapy shows promise against melanoma

Cell-based immunotherapy shows promise against melanoma

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre partner to address treatment gap for stage 2 melanoma patients

European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre partner to address treatment...

Researchers engineer cells to destroy malignant tumour cells but leave the rest alone

Researchers engineer cells to destroy malignant tumour cells but leave the rest alone

First results of the European AURORA study: towards a better understanding of the molecular changes driving metastatic breast cancer

First results of the European AURORA study: towards a better understanding of the molecular changes driving...

Immunotherapy may be effective for subset of prostate cancer

Immunotherapy may be effective for subset of prostate cancer

Novel risk score for predicting blood cancer relapse

Novel risk score for predicting blood cancer relapse

New technique for studying cancer mutations - approaches for future therapies

New technique for studying cancer mutations - approaches for future therapies

More from ecancer